en · de · es · pt
cjc-1295-notes.peptides6155.com › Wiki › Compound Identity And Development History — Evidence Review

Compound Identity And Development History — Evidence Review

By Editorial Desk · published 2026-07-22 · last reviewed 2026-08-01 · Wiki

lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

Background and Molecular Features

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

Cjc-1295 at a glance

PropertyValueNotes
Molecular formulaC152H252N44O42Cited for the form without the drug affinity complex
Molecular weightAbout 3368 DaReported value for modified GRF(1-29)
AppearanceWhite to off-white powderLyophilised solid as usually supplied
SolubilitySoluble in water and polar solventsClarity depends on purity and salt content
Typical storage-20 C or below, dryProtect from light and repeated warming cycles

CJC-1295 Background and Mechanism

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

Related pages on this site

Persistence, Stability and Measurement

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

Handling Storage and Quality Control

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Background from the literature

An FDA category that refers to medications used to treat diseases and conditions that occur rarely. There is little financial incentive for the pharmaceutical industry to develop medications for these diseases or conditions. Orphan drug status, however, gives a manufacturer specific financial incentives to develop and provide such medications. (NLM) Outcome

==== Disease resistant cultivars ==== Resistant varieties are available. In Indian cultivars, Nataraj et al. 2020 find that anthracnose caused by Colletotrichum truncatum is resisted by a combination of 2 major genes.

=== Clitoris === Located at the anterior junction of the labia minora is the clitoris, a highly erogenous sexual organ. The visible portions of the clitoris are the glans and frenulum. Typically, the glans is roughly the size and shape of a pea, and can vary in size from about 6 mm to 25 mm (less than an inch). The size can also vary when the clitoris is erect, which happens when two regions of erectile tissue known as the corpora cavernosa (along with the bulbs and crura, which both constitute the root of the clitoris) fill with blood, making the shaft engorged. The glans contains many nerve endings, which makes it highly sensitive. The only known function of the clitoris is to focus on sexual feelings. The clitoral hood is a protective fold of skin and it may partially or completely cover the shaft and glans. The hood may be partially or completely hidden within the pudendal cleft.

Sources: en.wikipedia.org

Further detail

Tramadol can have pharmacodynamic, pharmacokinetic, and pharmacogenetic interactions. Tramadol is metabolized by CYP2D6 enzymes which contributes to the metabolism of approximately 25% of all medications. Any medications with the ability to inhibit or induce these enzymes may interact with tramadol. These include common antiarrhythmics, antiemetics, antidepressants (sertraline, paroxetine, and fluoxetine in particular), antipsychotics, analgesics, and tamoxifen.- Due to tramadol's serotonergic effects, tramadol has the potential to contribute to the development of an acute or chronic hyper-serotonin state called serotonin syndrome when used concurrently with other pro-serotonergic medications such as antidepressants (SSRIs, SNRIs, tricyclics, MAOIs), antipsychotics, triptans, cold medications containing dextromethorphan, and some herbal products such as St. John's wort. Concurrent use of 5-HT3 antagonists such as ondansetron, dolasetron, and palonosetron may reduce the effectiveness of both drugs. Tramadol also acts as an opioid agonist and thus can increase the risk for side effects when used with other opioid and opioid-containing analgesics (such as morphine, pethidine, tapentadol, oxycodone, fentanyl, and Tylenol 3). Tramadol increases the risk for seizures by lowering the seizure threshold. Using other medications that lower seizure threshold – such as antipsychotic medications, bupropion (an anti-depressant and smoking cessation drug), and amphetamines – can further increase this risk.

== Cameroon == Modibbo Adama – Islamic scholar and first emir of Adamawa (Both Cameroon and Nigerian Adamawa) Ahmadou Ahidjo – first president, Cameroon (1960–1982) Bello Bouba Maigari – former prime minister, Cameroon Sadou Hayatou – former prime minister, Cameroon Issa Hayatou – former president of the Confederation of African Football (CAF), former acting president FIFA, Cameroon Oumarou Fadil – Businessman, Vice President of Group Fadil (an agro-industrial group which operates in several sectors including soap, oil extraction, tourism, livestock, and new information technologies), Cameroon Djaili Amadou Amal – Writer and feminist activist, Cameroon Goggo Addi – Storyteller who worked to preserve Fulani cultural heritage Souleymanou Hamidou Germaine Ahidjo - former first lady, Cameroon (1960–1982) Youssoufa Daoua (1947–2015), Cameroonian politician Mohamadou Bayero Fadil, Cameroonian businessman Abbo Aboubakar, Cameroonian businessman and politician Baba Ahmadou Danpullo, Cameroonian businessman Nana Bouba, Cameroonian businessman Marafa Hamidou Yaya, Cameroonian politician Garga Haman Adji, Cameroonian politician Mohamadou Dabo, Cameroonian businessman

===== Study of antimicrobial resistance ===== Nowadays to detect resistances of different microbes is used a technique called Antibiotic Sensitivity (AST), but several studies have discovered that bacterial resistance is in the genoma and it is transferred by horizontal way (HGT), so sequencing methods are being developed to ease the identification and characterization of those genomes and metagenomes. For the moment exist the following methods to detect antimicrobial resistances:

In general, a starting molecule is adhered to a solid support (typically an insoluble polymer), then additional reactions are performed, and the final product is purified and then cleaved from the solid support. Since the molecules of interest are attached to a solid support, it is possible to reduce the purification after each reaction to a single filtration/wash step, eliminating the need for tedious liquid-liquid extraction and solvent evaporation steps that most synthetic chemistry involves. Furthermore, by using heterogeneous reactants, excess reagents can be used to drive sluggish reactions to completion, which can further improve yields. Excess reagents can simply be washed away without the need for additional purification steps such as chromatography.

Sources: en.wikipedia.org

Supporting material

== January 8, 1982 (Friday) == To end a federal antitrust suit that had been brought in 1974 by the U.S. Department of Justice, the telephone monopoly American Telephone & Telegraph (AT&T) agreed to sell its 22 individual Bell System companies that had controlled most U.S. telephone lines. On the same day, the Department of Justice dropped its 12-year-old antitrust suit against International Business Machines (IBM), ending a trial that had started on May 19, 1975. The Umkhonto we Sizwe paramilitary force of South Africa's anti-apartheid African National Congress, carried out an attack on the construction site of the Koeberg Nuclear Power Station, planned to be the white South African government's first nuclear power plant, causing 500 million rands worth of damage and setting back the completion date by 18 months. The first White House meeting concerning Project Excalibur, the proposed Strategic Defense Initiative (nicknamed the "Star Wars defense") for the United States against an enemy missile attack, took place as Edward Teller, Karl Bendetsen, William Wilson and Joseph Coors made a one-hour presentation to U.S. President Ronald Reagan for a satellite with lasers that could destroy nuclear missiles after their launch.

She explained "For Ari, the attraction for Mac would be that he provides her with groundings. His energy allows her to feel safe and protected and I guess relaxed, because she can be quite a buzz in the brain, quite a stress head and that's something that really attracts her to his energy." Weir thought Ari was more likely to prioritise her, while Tane would bring too much drama and chaos into her life. Weir also told Kilkelly that as things between Ari and Mac become more serious, Mac finds that Tane is not "a temptation" and she can fully commit to Ari and their future. In scenes filmed in the Blue Mountains, Mac joins the brothers as they search for Nikau and his girlfriend Bella Nixon (Courtney Miller), who needs to return for a police interview. Weir said that Mac is pleased when Ari and Tane temporarily set aside their differences to find Nikau and Bella. While Mac is staying with the Paratas, Ari soon notices the tension between her and Tane. After Tane admits that he is struggling to be himself around Mac, she decides to move in with Ziggy Astoni (Sophie Dillman), just as Ari asks her to move in permanently. As Mac thinks the offer over, Ari runs out of patience and he questions whether she is as committed to their relationship as he is. Mac moves out and Ari takes his anger out on Tane, before his suspicions lead him to give Mac an ultimatum about the status of their relationship. The arrival of Ari's stepdaughter Chloe Anderson (Sam Barrett) and her mother Mia Anderson (Anna Samson) in February 2021 leads to the end of his relationship with Mac.

== Treatment == Solar purpura does not require treatment and may resolve on its own within weeks or months. The lesions may also be permanent. Many people seek treatment for cosmetic purposes. There have been several studies on possible future treatments. A common treatment involves Retinoic acid and other vitamin A derivatives in an attempt to increase dermal thickness and prevent extravasation of red blood cells. The most common treatment is to avoid UV exposure, apply sunscreen, and wear long-sleeved clothing.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.

Is CJC-1295 an approved medicine?

No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.

How does it differ from sermorelin?

Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.

What is the difference between CJC-1295 and natural GHRH?

Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.

Network